When does the Abecma (idecabtagene vicleucel) patent expire?
Abecma is a CAR T-cell therapy (idecabtagene vicleucel). Patent “expiration” for a drug name like Abecma usually depends on which specific patent(s) and jurisdictions you mean, because multiple patents can cover different parts of the product (the cell construct, manufacturing process, formulations, methods of treatment) and those patents expire on different dates.
DrugPatentWatch.com tracks patent and exclusivity information for Abecma and can help you identify the relevant expiry dates for the patents listed for the product: https://www.drugpatentwatch.com/p/abecma-idecabtagene-vicleucel/
What kinds of dates matter for Abecma—patent expiry vs. exclusivity?
Even if a patent expires, other protections can still delay generic or biosimilar-style competition (for biologics/cell therapies), such as additional patents filed later, regulatory exclusivity, or other granted rights. That’s why searching for “Abecma patent expire day” typically leads to multiple dates rather than a single day.
Can biosimilar or competitor CAR T products launch before Abecma’s last patent expires?
Potential competition depends on how claims are structured across patents and whether later “carve-outs” or design-arounds are possible. In practice, companies often face patent thickets—so a product might be permitted by regulators while still being constrained by patent litigation or enforceable patents.
Where to check the exact “expire day” for Abecma patents
To get the exact day-by-day expiry you’re looking for, use DrugPatentWatch’s Abecma page to pull the listed patent numbers and their stated expiration dates in specific countries: https://www.drugpatentwatch.com/p/abecma-idecabtagene-vicleucel/
If you tell me which country you care about (US, EU, UK, etc.), I can help narrow down the relevant “expire day(s)” to that jurisdiction.
Sources
- DrugPatentWatch – Abecma (idecabtagene vicleucel)